Free U.S. shipping on orders over $150
Limitless Labs

Retatrutide vs Tirzepatide vs Semaglutide: What the Research Shows

Last updated 2026-09-10
On this page+

Semaglutide, tirzepatide, and retatrutide represent three generations of incretin-based peptide design: one receptor, two receptors, and three. Semaglutide is a GLP-1 receptor agonist with nearly a decade of outcome-trial data behind it [2][4][5][6]; tirzepatide adds GIP receptor agonism and is FDA-approved for type 2 diabetes, chronic weight management, and obstructive sleep apnea with obesity [14][15][16]; retatrutide adds a third target — the glucagon receptor — and remains investigational, with phase 3 results reading out through 2026 [18][21][22]. This page places the three compounds' published trial records side by side. One caution frames everything below: the cited direct comparisons are tirzepatide versus semaglutide in SURPASS-2 (type 2 diabetes) [8] and SURMOUNT-5 (obesity without diabetes) [12], so most comparisons here are between separate trials with different populations, durations, and statistical methods — a fundamentally weaker form of evidence. This is a summary of the scientific literature, not medical guidance.

Side-by-Side Comparison

Semaglutide Tirzepatide Retatrutide
Receptor targets GLP-1 (mono-agonist) [1] GLP-1 + GIP (dual agonist) [7] GLP-1 + GIP + glucagon (triple agonist) [17]
Developer Novo Nordisk [1] Eli Lilly [7] Eli Lilly [17]
Development status FDA-approved: Ozempic (T2D, 2017), Rybelsus (oral, 2019), Wegovy (weight management, 2021) FDA-approved: Mounjaro (T2D, 2022), Zepbound (weight management, 2023; OSA with obesity, 2024) [14][15][16] Investigational; phase 3 topline results 2025–2026, no FDA approval established by these trial reports [21][22]
Key weight-trial results STEP 1: −14.9% at 68 wk vs −2.4% placebo [2]; STEP 5: −15.2% at 104 wk [4] SURMOUNT-1: −20.9% at 72 wk (15 mg) vs −3.1% placebo [9]; SURMOUNT-4: −25.3% cumulative at 88 wk with continued use [11] Phase 2: −24.2% at 48 wk (12 mg) vs −2.1% placebo [18]; TRIUMPH-1 (company-reported efficacy estimand): −28.3% at 80 wk; extension −30.3% at 104 wk in BMI ≥35 subgroup continuing treatment [21]
Key glycemic results SURPASS-2 comparator arm: HbA1c −1.86 points at 1 mg over 40 wk [8]; cardiovascular-outcome glycemic populations studied in SUSTAIN-6 [5] SURPASS-2: HbA1c −2.01 to −2.30 points across doses at 40 wk [8] Phase 2 T2D: HbA1c −2.02 points at 24 wk (12 mg) [19]; TRANSCEND-T2D-1: −1.94 points at 40 wk [20]
Half-life / administration in trials Extended half-life via albumin binding; once-weekly subcutaneous (oral tablet also studied) [1] ~5 days; once-weekly subcutaneous [7] ~6 days; once-weekly subcutaneous [17]
Evidence depth Deepest: completed CV outcome trials in diabetes (SUSTAIN-6) and non-diabetes (SELECT), kidney outcomes (FLOW) [5][6][13] Deep: CVOT vs active comparator completed (SURPASS-CVOT); placebo-controlled CV trial in obesity ongoing to ~2027 [10] Shallowest: no completed outcome trials; several phase 3 results are company topline reports awaiting peer review; CV/kidney outcomes trial runs to ~2029 [21][22]

Mechanism: One, Two, or Three Receptors

All three compounds are engineered single-chain peptides with fatty-acid modifications that extend half-life enough for once-weekly injection in trials [1][7][17], but they diverge in how many hormone receptors they engage.

Semaglutide activates only the GLP-1 receptor. GLP-1 receptor agonism enhances glucose-dependent insulin secretion, suppresses glucagon release when glucose is elevated, slows gastric emptying, and reduces appetite through central pathways [1]. This single mechanism produced the STEP, SUSTAIN, SELECT, and FLOW results and remains the reference point for the class.

Tirzepatide adds GIP receptor agonism — the other major incretin. Its receptor profile is deliberately imbalanced: GIP receptor affinity comparable to native GIP, with GLP-1 receptor affinity roughly fivefold weaker than native GLP-1 [7]. The working hypothesis in the pharmacology literature is that GIP signaling adds to appetite and insulin-secretion effects while improving the tolerability ceiling, though how much of tirzepatide's performance is attributable to GIP agonism versus its pharmacokinetics and biased GLP-1 signaling remains debated [7].

Retatrutide engages three receptors, adding glucagon receptor agonism to the incretin pair. Glucagon receptor activity increases hepatic energy expenditure and lipid oxidation — an "energy-output" mechanism layered on top of the appetite-suppressing "energy-input" mechanisms — and is the leading hypothesis for the unusually large liver-fat reductions seen in its MASLD substudy [17]. In vitro, retatrutide is most potent at the GIP receptor of its three targets [17].

What the Weight and Glycemic Trials Reported

Each compound's pivotal trials reported progressively larger mean weight reductions, but these figures come from separate trials and are not directly comparable (see the next section for why).

In semaglutide's STEP 1, adults with overweight or obesity but without diabetes lost a mean 14.9% of body weight at 68 weeks versus 2.4% with placebo [2], and STEP 5 showed that reduction was largely maintained at two years while treatment continued [4]. In tirzepatide's SURMOUNT-1, the corresponding figure was 20.9% at 72 weeks at the highest dose versus 3.1% with placebo [9]. In retatrutide's phase 2 obesity trial, mean reduction reached 24.2% at 48 weeks at the highest dose — with weight curves not yet plateaued [18] — and company-reported TRIUMPH-1 efficacy-estimand results report 28.3% at 80 weeks, with 30.3% at 104 weeks in the extension subgroup with baseline BMI ≥35 continuing treatment [21]. The retatrutide phase 3 figures are company press-release data that had not completed peer review at the time of writing [21][22].

On glycemia, tirzepatide's SURPASS-2 reported HbA1c reductions of 2.01–2.30 percentage points across doses versus 1.86 with semaglutide 1 mg over 40 weeks [8] — noting that semaglutide has since been studied at higher doses than the 1 mg used there. Retatrutide's phase 2 diabetes trial reported HbA1c reductions up to 2.02 points at 24 weeks [19], and phase 3 TRANSCEND-T2D-1 reported up to 1.94 points at 40 weeks [20]. A consistent pattern across all three programs: participants with type 2 diabetes lose less weight than participants without it [3][19][20].

Head-to-Head Status: What Has Actually Been Compared

Tirzepatide vs semaglutide — two published head-to-heads. SURPASS-2 compared them in type 2 diabetes: all three tirzepatide doses met superiority criteria against semaglutide 1 mg on both HbA1c and weight (e.g., −11.2 kg vs −5.7 kg at the highest dose over 40 weeks) [8]. SURMOUNT-5, published in 2025, compared maximum tolerated doses in 751 adults with obesity but not diabetes: in that trial, tirzepatide produced a mean weight reduction of 20.2% versus 13.7% with semaglutide at 72 weeks, and 31.6% of tirzepatide participants achieved at least 25% weight reduction versus 16.1% with semaglutide [12]. These two trials address different populations and comparator doses; their findings should be read separately.

Retatrutide vs tirzepatide: no head-to-head trials published. Retatrutide vs semaglutide: no head-to-head trials published. Any ranking that places retatrutide above the other two rests entirely on cross-trial comparison, which the literature itself cautions against. The trials differ in populations (baseline BMI, diabetes status, comorbidities), durations (48 to 104 weeks), estimands and statistical handling of dropouts, background lifestyle interventions, and eras of conduct. SURMOUNT-5 measured a 6.5-percentage-point difference directly under its own protocol [12]; subtracting results from unrelated trials would not provide equivalent evidence. Until a randomized trial pits retatrutide directly against either approved compound, the honest summary is that retatrutide's separate trials reported larger mean reductions, in different populations, over different timeframes [18][21] — not that any compound is proven superior.

Evidence Depth: The Dimension the Weight Numbers Hide

The three compounds differ as much in what is known about them as in what the trials reported. Semaglutide has completed placebo-controlled cardiovascular outcome trials in diabetes (SUSTAIN-6: 6.6% vs 8.9% major event rates [5]) and in overweight/obesity without diabetes (SELECT: ~20% relative reduction in major cardiovascular events across 17,604 participants [6]), plus a positive dedicated kidney-outcomes trial (FLOW, 24% lower risk of major kidney events [13]). Tirzepatide's SURPASS-CVOT established noninferiority against dulaglutide — an active comparator with proven cardiovascular efficacy — while superiority on its primary cardiovascular endpoint was not established [10]; its placebo-controlled cardiovascular trial in obesity without diabetes runs to about 2027. Retatrutide has no completed outcome trials; its cardiovascular and kidney outcomes study is estimated to complete around 2029 [22], and several of its phase 3 efficacy figures remain in press-release form [21][22]. Larger reported weight reduction and thinner long-term evidence currently travel together, in inverse order of development stage.

Full research overviews for each compound, including tolerability findings, liver and sleep-apnea data, and open questions, are in the individual articles: retatrutide, tirzepatide, and semaglutide.

References

  1. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380. DOI: 10.1021/acs.jmedchem.5b00726
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989–1002. DOI: 10.1056/NEJMoa2032183 · PubMed 33567185
  3. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971–984. PubMed 33667417
  4. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:2083–2091. DOI: 10.1038/s41591-022-02026-4 · PubMed 36216945
  5. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834–1844. PubMed 27633186
  6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221–2232. DOI: 10.1056/NEJMoa2307563 · PubMed 37952131
  7. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009. PMID: 30473097
  8. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519. PMID: 34170647
  9. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038. PMID: 35658024
  10. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409–2420. doi:10.1056/NEJMoa2505928. PMID: 41406444
  11. Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945. PMID: 38078870
  12. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26–36. doi:10.1056/NEJMoa2416394. PMID: 40353578
  13. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med 2024;391(2):109–121. DOI: 10.1056/NEJMoa2403347 · PubMed 38785209
  14. U.S. Food and Drug Administration. FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes (Mounjaro). Press release, May 13, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes
  15. U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management (Zepbound). Press release, November 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  16. Eli Lilly and Company. FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. Press release, December 20, 2024. https://www.prnewswire.com/news-releases/fda-approves-zepbound-tirzepatide-as-the-first-and-only-prescription-medicine-for-moderate-to-severe-obstructive-sleep-apnea-in-adults-with-obesity-302337722.html
  17. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID: 35985340
  18. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972. PMID: 37366315
  19. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi:10.1016/S0140-6736(23)01053-X. PMID: 37385280
  20. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407:2402–2413. doi:10.1016/S0140-6736(26)00967-0. PMID: 42250575
  21. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1, NCT05929066). Press release, May 21, 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
  22. ClinicalTrials.gov. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes). NCT06383390. https://clinicaltrials.gov/study/NCT06383390

This article summarizes published scientific literature for educational purposes only. Semaglutide and tirzepatide are FDA-approved prescription medicines available only through licensed pharmacies under medical supervision; retatrutide is an investigational compound not approved for any use. Research-grade material sold as a laboratory reference standard is a separate category that is not a drug product and is not for human use. Nothing here constitutes medical advice, and no statement has been evaluated by the FDA.

Disclaimer: Research materials supplied by Limitless Labs are intended strictly for in-vitro research and laboratory use only. They are not intended for human or animal consumption, therapeutic use, or any form of self-administration. They are not approved medicines. Where this library discusses an approved pharmaceutical, that product is distinct from research materials sold by Limitless Labs. This page is an educational summary of published research and is not medical advice. These statements have not been evaluated by the Food and Drug Administration.

Get research updates

Subscribe to the Limitless Labs newsletter for research insights and product updates. You can unsubscribe at any time.